Eurand Announces Data On Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs To FDA-Approved ZENPEP(R)

Links shared publicly online about this topic.

  • 1,085
    total visits

Eurand Announces Data On Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs To FDA-Approved ZENPEP(R)

medicalnewstoday.com —

Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. (NASDAQ: EURX), announced additional data from a post-hoc analysis of a Phase III clinical trial w

View full resource at medicalnewstoday.com

Tags: Pancreatic Disease, Cystic Fibrosis, Pharma, Clinical Trial

  • Share

Most Recently Shared on June 18, 2010 at 2:06 pm By:

mnt_gastro MNT Gastrointestinal

Eurand Announces Data On Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEP... http://mnt.to/3F2Z

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Cystic Fibrosis MNT Cystic Fibrosis

MNT Drug Approvals MNT Drug Approvals

Advertisement